Percutaneous Continuous Irrigation Combined With Transgastric Necrosectomy usingLAMS in Treatment of SAP (PCISLAMS)

August 17, 2022 updated by: Chinese Medical Association

Early Percutaneous Continuous Irrigation Assisted Vacuum Drainage Combined With Transgastric Necrosectomy Using Lumen Apposing Metal Stents in Treatment of Severe Acute Pancreatitis

Severe acute pancreatitis (SAP) is the most severe form of acute pancreatitis (AP) and Infection of pancreatic necrosis (IPN) have shown to be one of the decisive factors defining the severity of illness.

Minimally invasive techniques including endoscopy, laparoscopy, retroperitoneal approaches, etc., have recently been widely used for debridement because the procedure can further reduces surgical stress and performed not require general anesthesia, thereby reducing complications. Studies have shown that endoscopic transgastric necrosectomy can significantly reduced the proinflammatory response, complications, and hospital stay. Despite these advantages, there are some limitations with this approach. First, transgastric necrosectomy should be performed as late (about 4 weeks) in the course of the disease as possible to allow necrosis to wrap, since early debridement may result in a higher patient fatality rate. However, patients with SAP are often in a severely ill state due to sepsis or MODS at an early stage, which causes them unable to adhere to necrotic tissue encapsulation by conservative treatment. Second, the ideal patient to select for this approach has necrosis confined in the vicinity of gastroduodenal location. Last, up to 27% of IPN patients require additional percutaneous catheter drainage (PCD) after undergoing endoscopic transluminal therapy. This may be explained by the fact that dissemination of necrosis, digestive enzymes and inflammatory mediators from the necrotic tissue lumen to other parts of the abdominal cavity during endoscopic procedures.

Percutaneous catheter drainage (PCD) has always been the principal treatment measure for patients with AP at early stage (< 4 weeks) or those with collections or necrosis extending into deeper anatomical planes. Irrigation through peripancreatic drainage placed after open laparotomy has been the standard treatment for patients with AP who had undergone surgical necrosectomy. However, this proactive approach has not been widely used in the setting of PCD.

To adequate drainage and removal of necrosis, an early percutaneous continuous irrigation assisted vacuum drainage in combination with subsequent endoscopic transgastric necrosectomy which has not been reported so far was applied in critically ill patients with SAP.

Study Overview

Detailed Description

Severe Acute Pancreatitis (SAP) Treatment Protocol After admission, patients were given intravenous analgetics, omeprazole and somatostatin, and nasojejunal tubes were placed for EN. Once fever developed, broad-spectrum antibiotics were given empirically. If the patient was concomitant with shock, respiratory failure, and acute kidney injury, appropriate organ support was provided. Patients with biliary pancreatitis was given encoscopic retrograde cholangiopancreato graphy (ERCP) within 24 h after admission. When the patient was diagnosed with hyperlipidemic pancreatitis and plasma triglyceride ≥11.3 mmol/L, plasma exchange was administered immediately. All patients were given contrast enhanced CT within 48 hours after admission to identify the location and range of the necrosis and calculate the CT severity index (CISI).

Procedure All PCD and endoscopic procedures were performed under conscious sedation or local anesthesia. If the patient's condition progressively worsened, a multifunctional irrigation-assisted vacuum drainage tube was placed by the CT-guided Seldinger technique in each of the necrosis cavity. The tube was administered with continuous internal irrigation and vacuum drainage as described in below: (1) the end of the drainage tube (the adapter) was connected to a vacuum device that delivers a controlled negative pressure within the range of 8-10 kPa. (2) a large volume of 0.9% normal saline was infused into the necrosis cavity constantly (1500mL a day, 65mL an hour) through the durg entrance, allowing for continuous irrigation; (3) the inside drainage tube was flush by rapid manual injection of 50-100 mL 0.9% normal saline twice a day through the drug entrance and inject 20-50 mL of 0.9% normal saline daily through water entrance to prevent the tube from becoming blocked by necrosis, debris or omentum; (4) total irrigation and drainage volume were checked every 8 hours to keep the irrigation-drainage balanced. All tubes were checked daily and replaced when the tube was translocated or blocked. When the volume of irrigation exceeds the drainage 500 mL/day or if there were serious complications associated with the drainage tube, continuous irrigation and vacuum drainage should be stopped immediately and the tube was the traditional drainage was performed.

Approximately 4 weeks after disease onset or the formation of well-defined wall was confirmed by repeat CT scan, transgastric necrosectomy were performed by one or two experienced endoscopist under conscious sedation. Transgastric necrosectomy was repeated, mostly every three to five days, until all loosely adherent necrotic material were cleared and replaced by granulation tissue. In the course of the procedure, antibiotic administration was adjusted based on the results of the microbiological culture results. Subsequently, percutaneous irrigation was stopped and replace with simple drainage if the patient's condition continues to improved and the cavity confirmed by CT was resolution. If the drainage volume was less than 10 mL/day for 3 consecutive days, clamp the drainage tube and remove it finally.

Study Type

Observational

Enrollment (Actual)

8

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Jiangsu
      • Nanjing, Jiangsu, China, 210008
        • Nanjing Drum Tower Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients with SAP and IPN;SAP was diagnosed according to the revised Atlanta classification, which defined simultaneous persistent single or multiple organ failure >48h;IPN was considered when the following situations occur: persistent fever ≥38.5℃; increasing blood white blood cells (WBC), C-reactive protein (CRP) or procalcitonin; rapid deterioration of clinical deterioration; signs of gas was present in areas of necrosis. IPN is confirmed when the patient undergoes fine needle aspiration and the culture was positive.

Description

Inclusion Criteria:

  • Diagnosed with SAP
  • Concurrent IPN

Exclusion Criteria:

  • Age <18 years or > 80 years
  • Patients or family members disagreed with this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
The study group
We retrospectively analysis of 8 consecutive patients with SAP and IPN. SAP was diagnosed with persistent organ failure >48h. IPN was considered when the following situations occur: ≥38.5℃; increasing WBC, CRP or procalcitonin; rapid clinical deterioration; signs of gas was present in areas of necrosis.
All patients with SAP were given contrast enhanced CT scan within 48 hours after admission to identify the location and range of the necrosis. If the patient's condition progressively worsened, a multifunctional irrigation-assisted vacuum drainage tube was placed by the CT-guided Seldinger technique in each of the necrosis cavity. Subsequently, transgastric necrosectomy were performed by one or two experienced endoscopist under conscious sedation. The procedure was repeated until all loosely adherent necrotic material were cleared and replaced by granulation tissue. Percutaneous irrigation was stopped and replace with simple drainage if the patient's condition continues to improved and the cavity confirmed by CT was resolution. If the drainage volume was less than 10 mL/day for 3 consecutive days, clamp the drainage tube and remove it finally.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
mortality
Time Frame: Day28 after enrollment
28day-mortality
Day28 after enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PCD
Time Frame: From the first catheter placement to total catheter removal
duration of PCD
From the first catheter placement to total catheter removal
endoscopic procedures
Time Frame: through study completion, an average of 3 months
number of endoscopic procedures
through study completion, an average of 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Wenkui Yu, Ph.D, Study concept and study design

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2019

Primary Completion (Actual)

May 9, 2022

Study Completion (Actual)

August 14, 2022

Study Registration Dates

First Submitted

August 14, 2022

First Submitted That Met QC Criteria

August 17, 2022

First Posted (Actual)

August 19, 2022

Study Record Updates

Last Update Posted (Actual)

August 19, 2022

Last Update Submitted That Met QC Criteria

August 17, 2022

Last Verified

January 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Severe Acute Pancreatitis

3
Subscribe